Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series : World's leading Event Organizer

Back

Hiba Natsheh

Hiba Natsheh

The Hebrew University of Jerusalem, Israel

Title: Nasal administration of tramadol and oxytocin in animal model for pain using Phospholipid Magnesome carrier

Biography

Biography: Hiba Natsheh

Abstract

In a previous work, we have shown the ability of Phospholipid Magnesome to improve nasal drug delivery to brain. Here, we focus on the role of this carrier to enhance the antinociceptive effect of two central acting analgesic drugs, tramadol and oxytocin. More than a two-fold increase in tramadol brain concentration relative to controls was detected in 10 minutes (the first tested time point) following the drug nasal administration in Phospholipid Magnesome. In an in vivo experiment using the acetic acid induced pain mice model, we observed a rapid and improved antinociceptive effect of nasal treatment with these drugs, each incorporated in the new carrier. The treatments reduced significantly the number of writhes achieving a maximum possible effect (MPE%) of 67 and 62% for tramadol and oxytocin systems, respectively. On the other hand, a weak antinociceptive effect was noticed for the nasal control systems: water solution, a non-vesicular system and liposome. In conclusion, our data showed that administrating the two analgesic drugs nasally from Phospholipid Magnesome enhances their delivery to brain and improves pain treatment efficacy in animal model. Using the new carrier may help to design nasal products for noninvasive and efficient pain treatment with a rapid onset of action.